The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate

Khabirov F.A.; Khaĭbullin T.I.; Granatov E.V.; Shakirzianova S.R.; Babicheva N.N.; Kochergina O.S.; Rakhmatullina E.F.; Akhmedova G.M.; Aver'ianova L.A.; Yakupov M.A.; Sabirov Zh.F.

doi:https://doi.org/10.17116/jnevro20181183118-26

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khaĭbullin T.I.

Granatov E.V.

Shakirzianova S.R.

GAUZ «Republic clinical neurology center», Kazan, Russia

Babicheva N.N.

Kochergina O.S.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Rakhmatullina E.F.

Neurology and manual therapy department of state medical academy, Kazan, Russia

Akhmedova G.M.

Aver'ianova L.A.

Yakupov M.A.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Sabirov Zh.F.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate

Authors:

Khabirov F.A., Khaĭbullin T.I., Granatov E.V., Shakirzianova S.R., Babicheva N.N., Kochergina O.S., Rakhmatullina E.F., Akhmedova G.M., Aver'ianova L.A., Yakupov M.A., Sabirov Zh.F.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3): 18‑26

DOI: 10.17116/jnevro20181183118-26

Read: 5110 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Khabirov FA, Khaĭbullin TI, Granatov EV, et al. . The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):18‑26. (In Russ.)
https://doi.org/10.17116/jnevro20181183118-26

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79

Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53

Effectiveness and tolerability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98

Associations of polymorphic variants of CYP2C19*2, *17 with effectiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20

On the issue of choosing anesthesia methods: a comparison of general medicine and clinical dentistry. Stomatology. 2025;(1):76-80

Experience of using ribociclib in the therapy of metastatic breast cancer in a regional oncological dispensary. P.A. Herzen Journal of Oncology. 2025;(3):89-93

Costs of home-based respiratory support and oxygen therapy. Medical Technologies. Assessment and Choice. 2025;(3):93-102

Results of manual therapy in degenerative spine diseases with and without radiculopathy. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):47-55

Results of an open-label, randomized, multicenter, comparative study of clinical efficacy and safety of Pulmibud drug and Pulmicort drug in patients with partially controlled and uncontrolled persistent bronchial asthma. Journal of Respiratory Medicine. 2025;(3):33-38

Abstract:

Objective. To evaluate the efficacy and safety of the interferon beta-1b bioanalogue «infibeta» in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. Material and methods. The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS. Results. In all groups, there was a significant decrease in the AARR and an increase in the EDSS score (p<0,05) after 12 and 24 months of treatment (p<0,05) with the best indicators in groups 1—3. After 12 months of treatment, the number of patients without signs of MRI activity was higher in groups 1—3 (48—61%) than in groups 4 and 5 (47, 43%, respectively) (p>0,05). After 24 months of treatment, the number of patients without signs of MRI activity decreased to 41–46% in groups 1—3, and more significantly in group 4 (27%). The percentage of NEDA-3 achieving patients did not significantly differ in the groups (23—32%) after 12 months of treatment. After 24 months of treatment the NEDA-3 declined more in group 4 (19%), least of all in groups 1 and 2 (27, 25%, respectively) (p>0,05). In most cases, the observed adverse events were mild or moderate. Flu-like syndrome was observed rarely in groups 1 and 4 (p<0,05). Injection reactions were observed most commonly in groups 3 and 5 (p<0,05). Conclusion. Infibeta, while retaining all the advantages of high-dose interferon beta, has the best tolerability profile, which makes it one of the optimal first line disease-modifying therapy for treatment of patients with MS.

Keywords:

infibeta

interferon beta-1b

genfaxon-44

synnovex

aksoglatiran FS

efficacy

safety

NEDA-3

Authors:

Khabirov F.A.

Khaĭbullin T.I.

Granatov E.V.

Shakirzianova S.R.

GAUZ «Republic clinical neurology center», Kazan, Russia

Babicheva N.N.

Kochergina O.S.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Rakhmatullina E.F.

Neurology and manual therapy department of state medical academy, Kazan, Russia

Akhmedova G.M.

Aver'ianova L.A.

Yakupov M.A.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Sabirov Zh.F.

Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia

Close metadata

References:

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR. Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116(12):48-53. (In Russ.) https://doi.org/10.17116/jnevro201611612148-53
Boyko AN, Lashch NY, Sharanova SN, Zakharova MN, Trifonova OV, Simaniv TO, Lysogorskaya EV, Guryanova OE, Kotov SV, Iakushina TI, Lizhdvoy VY, Belova YA, Khabirov FA, Babicheva NN, Khaibullin TI, Granatov EV, Averyanova LA, Sazonov DV, Odinak MM, Trinitatsky YV, Tsukurova LA, Sergeeva AI, Ivanov RA, Shustova MS. Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study. Zh Nevrol Psikhiatr im S.S. Korsakova. 2016;116: 10(2):61-67. (In Russ.) https://doi.org/10.17116/jnevro201611610261-67
Dhib-Jalbut S, McFarland HF. Treatment of multiple sclerosis with interferon beta 1b. Baillieres Clin Neurol. 1997;6(3):467-480. PMID: 10101584.
Boster A, Bartoszek MP, O’Connell C, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing — remitting multiple sclerosis. Ther Adv Neurol Disord. 2011;4(5):319-332. https://doi.org/10.1177/1756285611422108
Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12(3):309-320. PMID: 16764344.
Khabirov FA, Averyanova LA, Babicheva NN, Granatov EV, Khaybullin TI, Shakirzianova SR. Analysis of the effectiveness and safety of interferon beta-1a biosimilar for intramuscular injection in the treatment of multiple sclerosis. Modern medicine: neurology/psychiatry. 2016;1(1):21-24. (In Russ.)
Popova EV, Boĭko AN, Vasil’ev AV, Davydovskaia MV, Zavalishin IA, Kotov SV, Krotenkova MV, Khachanova NV, Sharanova SN, Shchur SG, Iakushina TI. Results of a comparative clinical trial of the Russian Β — interferon-1b bioanalogue (infibeta). Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112(5):56-61. PMID: 22951783. (In Russ.)
Khabirov FA, Babicheva NN, Khaĭbullin TI, Aver’ianova LA, Granatov EV, Akhmedova GM. Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112:9(2):113-122. PMID: 23235429. (In Russ.)
Bakhtiiarova KZ, Bragina OV, Vlasov YaV, Greshnova IV, Evdoshenko EP, Ivanishenkova EI, Kairbekova EI, Karnaukhova EN, Korotkevich NA, Leliukhina AV, Protasov IS, Rybina EV, Sazhnev AI, Skoromets AA, Soldatova OA, Trinitatskiĭ YuV, Fedianin AS, Chelnokova SN, Shabanova VD, Sharipova RR, Shchegol’kova EA, Iampol’skaia-Gosteva IA. Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2014; 114(8):39-45. PMID: 25345629. (In Russ.)
Khabirov FA, Khaybullin TI, Granatov EV, Babicheva NN, Aver’ianova LA, Shakirzianova SR. Results of an open-label comparative randomized clinical trial of Axoglatiran FS (F-Sintez, Russia) efficiency and safety in comparison with Copaxone-Teva (Teva Pharmaceutical Industries Ltd., Israel) in patients with relapsing-remitting multiple sclerosis. Neuromuscular diseases. 2016;6(4):28-36. (In Russ.) https://doi.org/10.17650/2222-8721-2016-6-4-28-36
Borets OG, Govorukhina NF, Zverev KV, Boiko AN. A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116:2(2):63-67. (In Russ.) https://doi.org/10.17116/jnevro20161162263-67
Kasatkin DS, Spirin NN, Boiko AN, Stepanov IO, Spirina NN, Baranova NS. The results of an open prospective study of β-interferon biosimilars (an Yaroslavl’ cohort). Zh Nevrol Psikhiatr im S.S. Korsakova. 2016;116:2(2):68-73. (In Russ.) https://doi.org/10.17116/jnevro20161162268-73
Khabirov FA, Khaibullin TI. Multiple sclerosis: modern principles of diagnostic and treatment: monography. Kazan. 2017. (In Russ.)
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144-1151. https://doi.org/10.1212/01.WNL.0000156155.19270.F8
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
D’Amico E, Leone C, Zanghì A, Fermo SL, Patti F. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. J Neurol. 2016;263(9):1802-1809. https://doi.org/10.1007/s00415-016-8207-z